ArticleJCEM case reports2026
Bilateral Adrenal Metastases From Breast Cancer 14 Years After Remission: Diagnostic Value of "Adrenal Thickening".
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Adrenal thickening," a radiologic enlargement of the adrenal gland, with no discrete mass, often benign and nonfunctional, may represent early radiologic sign of malignancy. We present a 64-year-old woman with a history of left lobular breast adenocarcinoma treated with left mastectomy, chemotherapy, radiation, and 4 years of adjuvant hormonal therapy. She remained in remission for 14 years when a new, incidental finding of left adrenal thickening was noted on contrast computed tomography (CT). The patient was asymptomatic, without signs of adrenal hormonal excess. Follow-up imaging revealed bilateral nodular adrenal enlargement with predominant nodules with attenuation >10 Hounsfield units (HU) and high fluorodeoxyglucose (FDG) avidity on positron emission tomography-CT. Biochemical primary adrenal insufficiency was later diagnosed. Biopsy of the adrenal gland confirmed metastatic breast adenocarcinoma. She was initiated on hydrocortisone replacement and combined therapy with ribociclib and letrozole. This case highlights the importance of individualized evaluation of "adrenal thickening," especially in patients with a prior history of malignancy, regardless of the years of remission. Progressive imaging changes and high-risk features such as high FDG avidity and nodules with unenhanced CT attenuation greater than 10 HU should prompt further work-up. Pheochromocytoma must be excluded prior to biopsy due to overlapping imaging characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.